R&D IN BRIEF
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
QuatRx starts second pivotal trial for its SERM Ophena; Arcalyst significantly reduces gout flares; Novartis dumps antibiotic add-on Aurograb; more R&D, in brief